# Alexandria Real Estate Equities, Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Alexandria Real Estate Equities, Inc).

## Overview

Alexandria Real Estate Equities, Inc. is a Maryland corporation formed in 1994 that has elected REIT tax status and focuses on life science real estate. The company owns, operates, and develops Class A/A+ laboratory and office properties clustered into collaborative “Megacampus™” ecosystems located in major U.S. life science innovation hubs. Its business model combines long-duration leasing (often triple-net with contractual escalations) with a development pipeline and selective acquisitions in its cluster markets. Alexandria also provides strategic capital to life science companies through a venture capital platform, creating an additional (and more volatile) source of returns alongside rental income.

## Products & services

• Class A/A+ life science lab and office leasing (Megacampus™)
• Development and redevelopment of life science campuses
• Property operations and tenant services/amenities
• Acquisitions of properties in life science innovation clusters
• Real estate joint ventures (consolidated/unconsolidated)
• Venture capital investments in life science companies

- **Rental and related real estate operations** (85%) — Base rent and recoveries from operating life science properties, often structured as triple-net leases with escalations.
- **Development and redevelopment** (7%) — Ground-up development and repositioning of Class A/A+ life science properties within Megacampus ecosystems.
- **Real estate joint ventures and other real estate activities** (5%) — Economics from consolidated and unconsolidated real estate joint ventures and related property-level arrangements.
- **Venture capital and non-real estate investments** (3%) — Strategic capital and investment returns from a venture platform focused on transformative life science companies.

- Class A/A+ life science lab and office leasing (Megacampus™)
- Development and redevelopment of life science campuses
- Property operations and tenant services/amenities
- Acquisitions of properties in life science innovation clusters
- Real estate joint ventures (consolidated/unconsolidated)
- Venture capital investments in life science companies

## Customers

Alexandria’s customers are tenants that need specialized, high-quality lab and office space in proximity to research talent, capital, and scientific infrastructure. The tenant roster spans multinational pharmaceutical companies, public and private biotechnology companies, life science tools/services and medical device firms, and adjacent categories such as digital health, advanced technology, and agtech. It also leases to academic and medical research institutions, U.S. government research agencies, and non-profit organizations, which can anchor demand in key clusters. Leasing is designed to be sticky: a large portion of leasing activity is generated from existing tenants, and many leases include annual escalations and triple-net structures that shift operating costs to tenants.

- **Large-cap / investment-grade life science companies** (primary) — Lease significant lab/office footprints for R&D and collaboration; valued for credit quality and longer lease terms.
- **Emerging and mid-cap biotechnology companies** (primary) — Lease flexible, expandable lab space within Megacampus ecosystems to support growth and talent recruitment.
- **Research institutions and government agencies** (secondary) — Lease specialized facilities tied to research missions and funding cycles; can provide stable, long-term occupancy.
- **Adjacent innovation tenants (digital health, technology, agtech)** (secondary) — Lease space to access life science clusters and partners; adds diversification but can increase cyclicality.

- Pharmaceutical companies leasing R&D and lab space near top clusters
- Biotechnology firms needing scalable lab footprints as programs grow
- Life science tools/services and medical device companies near customers
- Academic and medical research institutions seeking research-adjacent space
- U.S. government research agencies leasing mission-critical facilities
- Digital health/technology and agtech tenants colocating with life science hubs
- Venture capital firms and ecosystem partners occupying campus environments

## Geography

Alexandria’s portfolio is concentrated in North America and is organized around U.S. life science innovation clusters rather than broad national diversification. Key markets cited in filings include Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City, where the company builds clustered Megacampus ecosystems near academic and medical research institutions and transit. As of year-end 2025, the asset base included approximately 35.9 million rentable square feet (RSF) of operating properties and 3.5 million RSF under construction, reflecting a sizable development footprint in these clusters. Geographic concentration increases exposure to local supply/demand dynamics, entitlement and construction conditions, and tenant funding environments that can vary meaningfully by cluster.

- North America-focused portfolio with U.S. life science cluster concentration
- Core clusters include Greater Boston and San Francisco Bay Area
- Other key markets: San Diego, Seattle, Maryland, Research Triangle, NYC
- Megacampus sites are positioned near research institutions and transit
- Large development pipeline ties returns to local construction/lease-up conditions
- Joint ventures add exposure to specific submarkets (e.g., Mission Bay)

## Strategy

Alexandria’s strategy centers on owning and developing Class A/A+ life science properties within collaborative Megacampus™ ecosystems in established innovation clusters. The campus model is designed for tenant optionality and scalability, allowing tenants to expand within the ecosystem and supporting retention and repeat leasing. The company complements organic development with targeted acquisitions in cluster markets, underwriting assets based on tenant quality, infrastructure capacity, and proximity to centers of innovation. It also uses long-standing relationships across real estate and life science to source tenants and opportunities, and it deploys strategic capital through a venture platform to deepen ecosystem connectivity (while accepting higher valuation volatility).

- **Scale Megacampus ecosystems in core life science clusters** (long-term) — Clustering supports tenant recruitment/retention and expansion demand within the portfolio.
- **Execute development and redevelopment pipeline of Class A/A+ projects** (medium-term) — New supply controlled by the company provides growth capacity and optionality for existing tenants.
- **Drive leasing economics through lease structures and tenant mix** (short-term) — Triple-net leases, escalations, and higher-credit tenants can stabilize cash flows and reduce expense volatility.

- Concentrate on Class A/A+ life science assets in AAA innovation clusters
- Build Megacampus ecosystems to drive tenant retention and expansion
- Maintain a development/redevelopment pipeline to meet tenant growth needs
- Pursue selective acquisitions near centers of innovation
- Underwrite for tenant credit quality and specialized building infrastructure
- Use industry relationships to source tenants and off-market opportunities
- Deploy strategic venture capital to strengthen ecosystem connectivity

## Risks

Alexandria’s performance is tied to demand for life science lab space in a handful of major U.S. clusters, so oversupply, tenant downsizing, or reduced venture funding can pressure occupancy and rental rates. Tenant credit risk is meaningful despite a large investment-grade/large-cap mix, particularly for smaller biotech tenants that depend on capital markets and R&D milestones to fund operations. Development and redevelopment introduce execution risk (cost inflation, delays, permitting, and lease-up), and the company also faces ground lease renewal/default risk where applicable. In addition, the venture investment platform and other non-real estate investments can create earnings volatility through fair value changes and impairments, and policy shifts (regulatory, funding, staffing, trade) by the U.S. government can affect tenants and portfolio companies.

- **U.S. government policy shifts affecting tenants and venture portfolio** [high] — Changes to regulatory, funding, staffing, and trade policies can disrupt R&D budgets and operating conditions for pharma/biotech, institutions, and government-related research activity.
- **Inability to complete or profitably operate acquisitions/developments** [high] — Returns depend on sourcing, underwriting, construction execution, and stabilizing occupancy in specialized lab assets.
- **Tenant inability to pay rent / re-leasing risk** [high] — Biotech and adjacent innovation tenants can face funding and industry-specific shocks that impair rent coverage and renewal demand.

- Life science leasing demand risk from biotech funding cycles and R&D budgets
- Cluster concentration risk (local oversupply or demand shocks in key markets)
- Development risk: cost inflation, delays, entitlements, and lease-up execution
- Tenant credit risk, especially among pre-profit biotech tenants
- Ground lease renewal/default risk and re-leasing risk on expiration
- Policy/regulatory shifts affecting tenants and venture portfolio companies
- Earnings volatility from non-real estate investment fair value and impairments

## Accounting

Key accounting judgments for Alexandria include purchase accounting for real estate acquisitions, which are generally treated as asset acquisitions with the consideration allocated to tangible and intangible assets and assumed liabilities based on relative fair values. These fair values rely on judgmental inputs such as comparable market data, replacement cost estimates, and discounted cash flow assumptions (e.g., NOI and capitalization rates), which can affect depreciation, amortization, and future gain/loss recognition. Impairment testing for real estate is also critical: held-and-used assets are evaluated using undiscounted cash flows, while held-for-sale assets are compared to expected sales price less costs to sell, and changes in assumptions can drive large non-cash charges. Finally, the company’s non-real estate investments (including venture investments) can introduce earnings volatility through unrealized gains/losses and impairments, which management highlights as distinct from property operating performance.

- **Accounting for real estate acquisitions as asset acquisitions** — Can materially change reported earnings profile and comparability across periods.
- **Impairment of real estate assets (held and used vs held for sale)** — Material impact on GAAP net income; typically excluded from FFO per Nareit guidance.
- **Fair value and impairment of non-real estate (venture) investments** — Increases earnings volatility and can obscure underlying property operating trends.

- Real estate acquisitions treated as asset acquisitions (allocation by fair value)
- Valuation inputs: comps, replacement cost, DCF/NOI and cap rates
- Impairment testing differs for held-and-used vs held-for-sale assets
- Potential large non-cash impairment charges can swing GAAP net income
- Non-real estate investments can create unrealized gain/loss volatility
- FFO metrics add back certain real estate impairment charges (non-GAAP)

---

*Last updated: 2026-09-24T11:35:23.004144+00:00*